Ajovy (fremanezumab-vfrm; Teva) is now available in an autoinjector device for the preventive treatment of migraine in adults.
The autoinjector device includes a button-free, push-down mechanism, as well as audible clicks to guide patients and caregivers through successful administration into the upper arm, thigh or abdomen. The autoinjector is for one-time use only and locks after use; a viewing window displays when the dose has been delivered. Administration of 1 dose of Ajovy via the prefilled autoinjector takes approximately 30 seconds.
Ajovy is available as a 225mg/1.5 mL solution in a single-dose prefilled autoinjector and in a single-dose prefilled syringe. Treatment can be administered either monthly (225mg) or quarterly (675mg).
Patients who are prescribed Ajovy 675mg every 3 months must use 3 separate autoinjectors or 3 separate syringes, administered as 3 consecutive subcutaneous injections of 225mg each; the same injection area for all 3 injections may be used but not the same spot.
The list price for the Ajovy autoinjector is $603.20.
For more information visit tevapharm.com.
This article originally appeared on MPR